Bridging academic borders: King's International fellowships in movement disorders and neuro-rehabilitation
King's Dubai's Parkinson's Centre of Excellence pioneers global clinical and research training
King's College Hospital London-Dubai is leading the way in international clinical and research training with its pioneering fellowships in Movement Disorders and Neuro-Rehabilitation. Notably, the programme has launched the first-ever Indonesian Visiting Fellowship in Dubai, fostering cross-border academic exchange and medical expertise.
Dr Merrie, a consultant in neuro-rehabilitation at EMC Hospitals in Jakarta, recently completed her fellowship in Movement Disorders and Parkinson's under the mentorship of Dr Vinod Metta, program director at King's College Hospital Dubai. Reflecting on her experience, she highlighted the invaluable opportunity to manage complex Parkinson's cases and advanced movement disorders. She also had the rare chance to witness and study conditions such as corticobasal degeneration, ocular apraxia, and alien limb syndrome - diseases she had previously only encountered in textbooks. Additionally, her hands-on training included administering EMG-guided botulinum injections for dystonia and spasticity, as well as managing elevated intracranial pressure, under the guidance of Dr Metta and professor Ray Chaudhuri.
Similarly, Mohammed, a neuro-physiotherapist, undertook a specialised Parkinson's neuro-rehabilitation training programme under Dr Metta's supervision. He was particularly impressed by the comprehensive, multidisciplinary approach at the Parkinson's Centre of Excellence, which seamlessly integrates neurophysiotherapy, speech and language therapy, and occupational therapy to manage patients across different races, ages, and stages of Parkinson's. He emphasised how the fellowship provided him with invaluable expertise in handling complex movement disorder cases, which will significantly benefit his work in Jakarta.
Both Dr Merrie and Mohammed extended their heartfelt gratitude to EMC Hospitals' management - Pak Jusup, Dr Juni, Dr Metta, and Dr Sedjaya - for nominating them for this prestigious overseas training. They also expressed appreciation to King's Dubai's management team, including Kimberley Pierce and Norafiz Gee, for their support. A special mention was given to the programme directors, Dr Vinod Metta and professor Ray Chaudhuri, along with esteemed mentors Dr Guy Chung-Faye, Dr George Kapsas, Dr Nicandro, and Dr John, for their invaluable guidance.
Dr Metta emphasised that King's Dubai's Parkinson's Centre of Excellence is committed to delivering world-class visiting fellowships. These programmes offer neurology residents, junior neurologists, neuro-rehabilitation consultants, and neuro-physiotherapists in-depth, hands-on training in managing a wide spectrum of movement disorders and Parkinson's disease. Fellows also gain expertise in neurophysiology, neuroradiology, and neuro-spine. He expressed his satisfaction with the overwhelmingly positive feedback from the first cohort of visiting fellows and looks forward to expanding the initiative further.
This groundbreaking fellowship initiative reinforces King's Dubai's commitment to advancing global medical training and fostering cross-border knowledge exchange in movement disorders and neuro-rehabilitation.
For more information about King's movement disorders, Parkinson's and neuro-rehabilitation training, as well as short-term visiting fellowships and PhD/doctoral programmes, please contact: ehabadly.awad@kch.a
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
an hour ago
- Zawya
CorroHealth makes strategic investment in Gulf Capital's Santechture
Abu Dhabi – Gulf Capital, one of the largest private equity firms investing from the GCC to the rest of Asia, announced today that global healthcare technology company CorroHealth has made a strategic investment into one of its portfolio companies, Santechture, a Dubai based pioneering revenue cycle management (RCM) intelligent technology solutions provider. The deal brings together the industry-leading AI capabilities of CorroHealth with the advanced RCM solutions of SANTECHTURE, equipping SANTECHTURE healthcare clients across the Gulf Cooperation Council (GCC) region with powerful new technology to maximize ROI. The investment formalizes what has been a productive working relationship between the two companies. Over the past two years, CorroHealth and SANTECHTURE have successfully completed multiple proofs of concept for SANTCEHTURE clients. In January, SANTECHTURE and CorroHealth jointly hosted the Arab Health reception focused on AI and Revenue Cycle Management (RCM) Innovation. SANTECHTURE, which is backed by leading institutional investors Gulf Capital and Shorooq Partners, has seen a phenomenal increase in demand for its advanced deep tech RCM solutions in the GGC and across regional markets, and this partnership will support yet another leap ahead in advancing innovation and value creation. CorroHealth CEO Pat Leonard said, 'This is an exciting step forward for CorroHealth, as we combine our technological capabilities with a local company based in the GCC region. CorroHealth joining forces with SANTECHTURE brings the best of both worlds to provide clients in the region with unsurpassed RCM capabilities to protect hospitals' bottom lines and help to ensure their financial future.' SANTECHTURE Founder and CEO Anas Batikhi said, 'The pairing of SANTECHTURE's unique leading-edge solutions with CorroHealth's AI driven innovations in the RCM technology space is truly unrivalled. We are especially thrilled to be cementing further our working relationship with CorroHealth and leading the intelligent automation drive to support our clients and partners with their RCM digital transformation journey, delivering on cost reduction and improved revenue outcomes.' Gulf Capital Managing Director Mohammad Madani added, 'We are proud to have been early backers of SANTECHTURE and to now support this landmark partnership between SANTECHTURE's and CorroHealth. This strategic investment is a strong validation of SANTECHTURE's leadership in intelligent RCM solutions across the GCC and marks a pivotal milestone in its growth journey. We are confident this collaboration will unlock significant value for healthcare providers in the region.' Bilal Mushtaq, MD, CorroHealth's Executive Vice President of Global Growth and Strategy for GCC market expansion said 'This strategic investment and partnership marks a pivotal step forward in our growth strategy, reinforcing our commitment to innovation and delivering greater value to a new market. This is not just a collaboration but a shared vision to forge a new path towards providing excellence in revenue cycle management'
The National
6 hours ago
- The National
Prozac users in the UAE concerned as supplies of 'life-changing' drug dry up
Prozac users in the UAE are concerned about dwindling supplies after its global discontinuation last year, sparking conversations among patients and psychiatrists about available alternatives. Considered a cornerstone treatment for conditions like depression and anxiety, the medication is now fast disappearing from pharmacy shelves as stocks dry up. Internationally, the medication is widely available under other brand names however in the UAE Prozac has historically been the only option with this formula. Finding alternatives Prozac, which was manufactured by US drug company Lilly, is the brand name for fluoxetine, a type of medication known as a selective serotonin reuptake inhibitor (SSRI). It has been used for mental health conditions, including depression, anxiety, obsessive-compulsive disorder, premenstrual dysphoric disorder and bulimia nervosa since its launch in 1987. It is available on the market as a controlled medication and accessible to patients when prescribed by a psychiatrist. Now, patients may have to source their medication out of the country or try alternative pharmaceuticals, such as Zoloft (sertraline) or Cipralex (escitalopram), which have different base formulations and therefore different side effects depending on a person's biology. 'This decision is not related to the safety or efficacy of the medicine, but reflects the availability of broad alternative treatments and evolving business priorities,' a Lilly spokesperson told The National. 'We encourage patients currently on Prozac to speak to their healthcare provider about treatment options available to them. While no new supplies are being planned, limited stock may still be available locally through licensed distributors.' The National was able to locate some Prozac at pharmacies with leftover stocks at the time of writing, but many contacted were completely out. Global antidepressants usage While Prozac has been one of the most widely prescribed drugs of its kind for decades, the global antidepressant market is growing rapidly. It was valued at $18.7 billion in 2024 and is estimated to increase at a compound annual growth rate of 7.5 per cent from 2025 to 2034, when it is forecasted it will be worth $37.9 billion, according to Global Market Insights. This is being driven predominantly by mental health awareness and rising demand for effective treatments for various conditions. 'Impact was life-changing' One Dubai-based mother, who wished to remain anonymous, is concerned for her 11-year-old daughter, who has been taking Prozac for the past 18 months. "She is autistic and struggles with severe anxiety, OCD and specific phobias," she told The National. "We tried other SSRIs before, but none were effective. Prozac has been the only medication that made a noticeable difference, particularly for her OCD symptoms." The mother said since they'd heard Prozac is going out of stock in the UAE, they've been trying to source an alternative fluoxetine product from their home country. "Switching to another SSRI is not a viable option for her right now ... I trust that the authorities will take this matter seriously and work toward a solution, especially for children and families who rely on this medication for daily functioning and well-being." Dubai resident Victoria McKeown, who lived with 'crippling' anxiety for years until she was prescribed Prozac, is also concerned about the lack of availability in the future. 'While I wouldn't describe myself as clinically depressed, I tried several antidepressants over the years with little effect,' she told The National. 'That changed when I was prescribed a low dose of Prozac. The impact was life-changing – not just for me, but for those around me.' Ms McKeown's psychiatrist contacted her to say she will need to consider trying medications that had previously been ineffective. 'Right now, it seems my only option is to travel overseas, obtain a prescription there, and bring it back with me," she said. "It's incredibly disheartening that a medication which has helped so many people is no longer available here.' Experts are hopeful that an appropriate alternative will soon be available in the market, however. Dr Teizeem Dhanji, a child and adolescent psychiatrist and medical director at Dubai's Sage Clinics, said there is currently no confirmed guidance from authorities, but 'it is expected that substitute options will be introduced in due course'. The National has contacted the Emirates Drug Establishment for more details on when an alternative will be registered, but there was no confirmation at the time of writing. What patients can do now Dr Dhanji advised individuals taking fluoxetine to consult their treating psychiatrists to discuss the best course of action. 'Clinicians can help develop a personalised plan to safely and gradually taper the current medications and transition to an appropriate alternative if necessary," she said. "There are a number of safe and effective antidepressant options available in the UAE and so patients should consult their psychiatrist early.' It may also give some individuals the chance to reassess treatment needs and explore additional coping strategies or therapeutic options that may complement or replace medication, Dr Dhanji added. But the disruption could have a significant impact on the market, said Antony Bainbridge, head of clinical services and clinical lead at Resicare Alliance, a UK-based assessment and residential provider for children with mental health issues that plans to open a Dubai boarding facility soon. Mr Bainbridge said the lack of a substitute could require potentially disruptive changes in medication, particularly for patients who respond well to fluoxetine. 'Alternative SSRIs like sertraline, citalopram and paroxetine are available, but they have different side effect profiles and may not be as effective for every individual.' Patients switching from Prozac to another SSRI may experience withdrawal symptoms, relapse or other side effects during the transition, he added. 'The unavailability may lead to worsening of symptoms in some patients, increasing the burden on mental health services.' Mr Bainbridge also expressed concerns that patients could resort to unregulated or illegal sources to obtain the medication, 'posing significant safety risks'.
Zawya
a day ago
- Zawya
Al Jalila Foundation receives AED 10mln from Commercial Bank of Dubai
Dubai, UAE: Al Jalila Foundation, the philanthropic arm of Dubai Health, announced a generous AED10 million donation from Commercial Bank of Dubai (CBD) to support the construction and development of Dubai Health's Hamdan Bin Rashid Cancer Hospital, Dubai's first fully integrated and comprehensive cancer care facility. This partnership reflects a shared commitment to advancing human health and underscores the importance of strategic collaboration between national institutions to enhance access to world-class medical services, particularly in the field of oncology. The donation agreement was signed during an official visit to the Foundation by H.E. Ahmad Abdulkarim Julfar, Chairman of Commercial Bank of Dubai, and Dr. Amer Al Zarooni, CEO of Al Jalila Foundation. His Excellency and the accompanying delegation were briefed on the Foundation's core programs and future initiatives. The signing ceremony was attended by Dr. Amer Sharif, CEO of Dubai Healthcare City, and Dr. Abdullah Al Khayat, CEO Emeritus of Al Jalila Children's Hospital. H.E. Ahmad Abdulkarim Julfar said: 'Our support for the Hamdan Bin Rashid Cancer Hospital reflects our deep-rooted commitment to serving the community and supporting individuals in need of advanced medical care. This partnership is aligned with the UAE's longstanding approach to fostering philanthropy in the healthcare sector and upholding the values of compassion and community solidarity.' Dr. Amer Al Zarooni, CEO of Al Jalila Foundation, expressed his gratitude: 'We thank Commercial Bank of Dubai for its generous contribution to a project that marks a major step forward in Dubai's healthcare landscape. This partnership reflects the power of collaboration in supporting national efforts to enhance cancer care and improve patients' lives.' The 59,000 square metres Hamdan Bin Rashid Cancer Hospital is being developed with the aid of donations received through Al Jalila Foundation, which leads Dubai Health's giving mission. Set to become a world-class medical institution, the hospital will be equipped with the latest diagnostic and therapeutic technologies and staffed by a highly qualified team of specialist doctors and trained nurses. It will also play a pioneering role in cancer research and education, focusing on developing innovative treatments and investing in the training of future medical and nursing professionals. Spanning G+8 floors, the Hamdan Bin Rashid Cancer Hospital designed with input from cancer survivors to ensure a truly patient-centered environment. The hospital was awarded Gold in the Future Healthcare Projects category by World Architecture News. Once operational, it will provide advanced, integrated cancer care to the patients. Al Jalila Foundation continues to forge strategic partnerships with corporations, institutions, and philanthropists to ensure that advanced medical care remains accessible to those in need, while contributing to the nation's vision of a healthier society, aligned with the goals of the Dubai Social Agenda 33. About Al Jalila Foundation Al Jalila Foundation, that leads Dubai Health's giving mission, is a global healthcare charity transforming lives through medical innovation. Established in April 2013 under the directives of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, the foundation works to position Dubai and the UAE at the forefront of medical advancement. The foundation provides essential treatment for those unable to afford healthcare, funds scholarships for medical professionals, and supports pioneering research addressing critical health challenges, including cancer, cardiovascular diseases, diabetes, obesity, and mental health.
